Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient scheduling and engagement platform for multi-specialty practices, combining intelligent scheduling, reminders, and digital intake. Franklin TN, raised $41M+.
Relatient is a patient engagement and scheduling company that provides healthcare providers with an integrated platform for scheduling automation, appointment reminders, digital check-in, and patient communication. Founded in 2013 and headquartered in Franklin, Tennessee, Relatient has raised more than $41 million and serves health systems, hospital outpatient departments, and multi-specialty physician groups across the United States. The company's Dash platform delivers intelligent self-scheduling, automated reminder workflows, digital intake forms, and post-visit survey capabilities through a single system that integrates with major EHR and practice management software.\n\nRelatiently's Dash scheduling platform is built around intelligent appointment matching, directing patients to the right provider, location, and appointment type based on clinical criteria and insurance requirements rather than offering a simple open calendar view. This smart scheduling approach reduces scheduling errors and the downstream revenue cycle problems they cause, while improving the patient experience by eliminating the friction of calling and navigating phone trees. The platform supports scheduling across complex multi-provider, multi-location organizations where routing rules are an important operational requirement.\n\nRelatiently competes in a market that has grown significantly as providers recognize the revenue and operational impact of patient access optimization. The company differentiates through its depth of EHR integration, its focus on enterprise multi-specialty environments, and its comprehensive approach to the full patient engagement lifecycle from first contact through post-visit follow-up. Relatient's combination of scheduling intelligence and communication automation serves as an integrated patient access solution for organizations that need more than basic reminder tools.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.